Article
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
BMC cancer - 16 Sept 2021
Ai Xinghao, Song Zhengbo, Jian Hong, Zhou Zhen, Chen Zhiwei, Yu Yongfeng, Li Ziming, Lu Shun
Abstract excerpt
BACKGROUND: Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors (afatinib, neratinib, and dacomitinib), anti-HER2 antibody drug conjugate (ADC) trastuzumab emtansine, and an emerging irreversible tyrosine kinase inhibitor (TKI) poziotinib were modest. Another new ADC trastuzumab deruxtecan showed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.